Basic Bempedoic Acid Information

• INN (International Nonproprietary Name): Bempedoic acid.
• Brand Names Available In Australia: Nexletol (bempedoic acid 180 mg) and Nexlizet (fixed combination 180 mg/10 mg) marketed with distribution support from CSL Seqirus and Esperion Therapeutics.
• ATC Code: C10AX21.
• Forms & Dosages: Film‑coated tablets 180 mg (monotherapy) and 180 mg/10 mg fixed‑dose combination with ezetimibe.
• Manufacturers In Australia: Esperion Therapeutics as originator and CSL Seqirus as distributor in Australia and New Zealand.
• Registration Status In Australia: Approved for supply in Australia (marketed brands include Nexletol and Nexlizet); specific ANMDMR registration details not specified.
• OTC / Rx Classification: Prescription only (Rx) in Australia.

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Are you wondering whether bempedoic acid really lowers heart risk, not just cholesterol numbers?

High‑quality evidence between 2022 and 2025 focuses on the CLEAR Outcomes programme and pooled analyses that followed the trial results.

The CLEAR Outcomes study was an international, event‑driven randomised trial conducted largely in adults with statin intolerance and it reported meaningful reductions in LDL‑C and fewer major adverse cardiovascular events versus placebo.

Smaller randomised trials and meta‑analyses from 2022–2024 confirm consistent LDL‑C reductions generally in the order of about 15–25% when bempedoic acid is used as monotherapy.

Combination therapy with ezetimibe produces larger LDL‑C reductions than bempedoic acid alone, which supports use of fixed‑dose products such as Nexlizet or Nustendi for patients needing greater lowering.

Australian registry snapshots and hospital audits emerging in 2023–2025 show early adoption of bempedoic acid in specialist lipid clinics and growing GP referrals for patients with statin intolerance.

Main Outcomes

The primary trial endpoints emphasise two linked goals: LDL‑C lowering and reduced composite cardiovascular events such as myocardial infarction and stroke.

Evidence indicates that LDL‑C reductions translate into fewer cardiovascular events in the populations studied, particularly where statins could not be tolerated.

Combination with ezetimibe provides additive LDL‑C lowering and is an effective escalation step when single‑agent therapy does not reach targets.

Safety Observations (TGA Reports)

TGA pharmacovigilance data in Australia mirror international safety signals for bempedoic acid.

Reported safety signals include increased serum uric acid with an associated risk of gout flares, small rises in hepatic enzymes, and rare tendon‑related events.

Overall the safety profile observed in post‑market surveillance is consistent with trial data and supports monitoring strategies described in product information.

Clinical Mechanism Of Action

Layman’s Explanation

How does bempedoic acid lower cholesterol in plain terms?

Bempedoic acid is an oral tablet that reduces the liver’s production of cholesterol by inhibiting ATP citrate lyase (ACL), an enzyme a step upstream of the HMG‑CoA reductase target of statins.

The drug lowers the raw material the liver uses to make cholesterol, and this helps more LDL particles to be cleared from the blood.

Scientific Breakdown

Bempedoic acid is a prodrug that is activated mainly in hepatocytes and thereby becomes an ACL inhibitor in the liver rather than in skeletal muscle cells.

Activation in hepatocytes reduces the chance of muscular toxicity experienced with statins, which is relevant when treating statin‑intolerant patients.

Once active, it decreases cholesterol biosynthesis and upregulates hepatic LDL receptors, increasing clearance of circulating LDL‑C.

Standard dosing is once daily at 180 mg, and hepatic activation explains the low myotoxicity signal compared with statins.

The mechanism is complementary to ezetimibe, which blocks intestinal cholesterol absorption, so combining both drugs yields additive LDL‑C reductions.

Pharmacokinetic features include oral absorption with once‑daily steady state, no routine dose adjustment for older adults, and caution for patients with severe renal or hepatic impairment.

Scope Of Approved And Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

What is bempedoic acid approved for in Australia?

Bempedoic acid (Nexletol) and fixed‑dose combinations (Nexlizet/Nustendi) are TGA‑approved for adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet and to maximally tolerated statin therapy, and for statin‑intolerant patients.

Products are prescription only and, as of 2025, broad PBS subsidy is limited and subject to future listing decisions.

Most access currently occurs via private prescription or specialist pathways rather than universal PBS coverage.

Notable Off‑Label Trends In Australian Practice

Clinicians in specialist practice sometimes consider bempedoic acid off‑label for adults with familial hypercholesterolaemia when PCSK9 inhibitors are not accessible or tolerated.

Another specialist‑led trend is short‑term use to bridge lipid control during pregnancy planning, although bempedoic acid is contraindicated in pregnancy and requires careful planning and contraception where relevant.

Off‑label uses are generally documented with shared decision‑making and specialist oversight rather than routine primary care prescribing.

Dosage Strategy

General Dosing

What dose should most adults expect to take?

The standard adult dose is 180 mg taken orally once daily and it may be taken with or without food.

Fixed‑dose combination tablets contain 180 mg bempedoic acid plus 10 mg ezetimibe for patients requiring additional LDL‑C lowering.

Children are not approved, and elderly patients typically use the standard adult dose without routine adjustment.

Condition‑Specific Dosing (PBS Recommendations)

Begin therapy at 180 mg once daily for primary hypercholesterolaemia or mixed dyslipidaemia and reassess LDL‑C after 4–12 weeks to judge response.

For statin‑intolerant patients use bempedoic acid as monotherapy when statins are not tolerated.

For patients already on a maximally tolerated statin consider adding bempedoic acid, or switch to the fixed‑dose combination with ezetimibe (Nexlizet/Nustendi) if the LDL‑C target remains unmet.

Use caution or avoid in severe renal impairment (eGFR <30 mL/min/1.73 m²) and in moderate‑to‑severe hepatic impairment, and arrange closer monitoring in these situations.

Safety Protocols

Contraindications (Australian Guidelines)

Who should not take bempedoic acid?

Absolute contraindications include known hypersensitivity to bempedoic acid or excipients, and pregnancy or breastfeeding.

Use is discouraged in severe hepatic impairment and should be used with caution in severe renal impairment.

Patients with known hyperuricaemia or a history of gout require baseline assessment and careful monitoring during therapy.

Adverse Effects (Post‑Market Pharmacovigilance)

Common adverse effects observed in trials and post‑market reports include rises in uric acid, gout flares, muscle spasms, back pain, upper respiratory infections, abdominal pain or diarrhoea, fatigue, and mild elevations in liver enzymes.

Rare but serious events reported include tendon rupture and hypersensitivity reactions, which warrant immediate review and cessation if suspected.

Australian TGA surveillance is consistent with international safety reporting and pharmacists should instruct patients to report signs of gout, significant muscle or tendon pain, or jaundice promptly.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Can I take bempedoic acid with my usual diet and a few drinks?

Bempedoic acid may be taken with or without food and has no clinically important interactions with common Australian dietary patterns such as coffee intake.

Alcohol does not interact directly with bempedoic acid but can increase the risk of gout flares and contribute to liver strain, so counsel patients to moderate alcohol intake if they have elevated urate or liver enzyme abnormalities.

Drug Combinations To Avoid (TGA Safety Alerts)

There are no major CYP‑mediated interactions that commonly alter bempedoic acid exposure, but prescribers should be cautious when combining with other agents that raise uric acid, such as some diuretics.

Co‑prescribing with statins is generally safe and provides additional LDL‑C lowering without the myopathy signal associated with statins, due to the hepatocyte‑selective activation of bempedoic acid.

Avoid use during pregnancy and monitor hepatic and renal function when combining with other hepatotoxic or renally cleared medicines.

Patient Experience Analysis

Australian Survey Data

What do patients say after starting bempedoic acid?

Emerging surveys from 2023–2025 in lipid clinics and community pharmacies show patients report objective LDL‑C reductions and improved cholesterol control.

Statin‑intolerant patients frequently report fewer muscle symptoms on bempedoic acid than they experienced with statins, which supports adherence where cost is not a barrier.

Adherence at 3–6 months appears comparable with other long‑term oral therapies when out‑of‑pocket costs are manageable.

Forum And Pharmacy Trends

Online forums and pharmacy enquiries reveal price sensitivity and frequent questions about PBS eligibility and co‑payment costs.

Community pharmacists play a vital counselling role in Australia, advising on gout risk, signs of tendon problems, management of missed doses, and when to seek medical review.

Rural patients often report longer waits for specialist review and higher out‑of‑pocket costs due to travel and limited local stock availability.

Distribution And Pricing Landscape

National Pharmacy Chains

How easy is it to find Nexletol or Nexlizet at major pharmacies?

Distribution in Australia is managed via CSL Seqirus in partnership with Esperion, and availability at chains such as Chemist Warehouse, Priceline and TerryWhite varies by stock and prescription pathways.

Pharmacies will often order stock on request if the item is not held routinely on the shelf.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth and electronic prescriptions have expanded access so patients can obtain prescriptions remotely and have medications delivered.

In our online pharmacy, bempedoic acid is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Prescribers must still ensure appropriate monitoring when prescribing remotely, and patients should be wary of overseas sellers that bypass Australian regulatory safeguards.

PBS Vs Private Cost Comparisons

As of 2025, PBS listing for broad subsidy is limited and many patients obtain bempedoic acid on private scripts, which means variable out‑of‑pocket costs depending on the brand and whether the fixed‑dose combination is used.

Patients commonly compare prices between community pharmacies and online suppliers and may seek manufacturer patient assistance programmes when available.

Alternative Options

Comparison Of PBS And Non‑PBS Options

What are common alternatives to bempedoic acid?

• Maximally tolerated statins such as atorvastatin or rosuvastatin remain first‑line for LDL‑C lowering and are generally PBS‑available.
• Ezetimibe is an inexpensive oral option, often PBS‑listed, and pairs well with bempedoic acid for extra LDL‑C reduction.
• PCSK9 inhibitors like alirocumab and evolocumab offer large LDL‑C reductions but are injectable and typically more costly and specialist‑accessed.

Pros And Cons Checklist

Pros of bempedoic acid include an oral route, utility as a statin alternative for intolerance, and additive benefit with ezetimibe.

Cons include limited PBS coverage for many patients, a modest LDL‑C lowering effect versus PCSK9 inhibitors, and the increased uric acid and gout risk.

Choice depends on cardiovascular risk, LDL‑C target, cost, route preference, and access to specialist therapies.

Regulatory Status

TGA Approval Framework

Bempedoic acid is prescription only in Australia and approved by authorities following assessment of safety, quality and efficacy.

The product is marketed through Esperion and distributed locally by CSL Seqirus, consistent with approvals in jurisdictions such as the US and EU.

PBS Subsidy Process

PBS listing requires formal cost‑effectiveness submissions and negotiation with the Pharmaceutical Benefits Advisory Committee and government.

Clinicians should check the current PBS Schedule for up‑to‑date subsidy status and consider private prescribing or patient access schemes while monitoring any TGA safety advisories.

Consolidated FAQ

Can I get bempedoic acid on the PBS?

Answer: PBS listing is limited as of 2025 and many Australian patients currently pay privately or use specialist access schemes for Nexletol or Nexlizet.

Is it safe with a history of gout?

Answer: Bempedoic acid raises uric acid and can precipitate gout; assess baseline urate and manage gout risk before and during therapy.

Can I stop statins and switch?

Answer: For patients genuinely intolerant of statins, clinicians may use bempedoic acid, but do not stop statins without medical advice and an agreed plan.

How soon will my LDL‑C drop?

Answer: Expect to reassess LDL‑C at 4–12 weeks to judge the treatment effect and adjust therapy if targets are not met.

Can I buy online?

Answer: Prescription is required in Australia for supply through regulated channels; be cautious with overseas suppliers that may not meet Australian regulatory standards.

Visual Guide

If you work in a pharmacy, what visual aids help patients decide?

Recommended infographics include a PBS pricing versus private cost flowchart, a treatment pathway diagram that shows statin intolerance → bempedoic acid monotherapy → add ezetimibe → consider PCSK9 inhibitor, and a safety monitoring checklist for urate, liver function tests and tendon symptoms.

Use simple colour coding on cards to show rural versus urban access and pharmacy pickup versus mail order.

Community pharmacies can display comparison cards that summarise Nexletol, Nexlizet and ezetimibe to speed counselling and shared decision‑making.

Storage And Transport

Household Storage Under Australian Climate

How should patients store bempedoic acid at home in Australia?

Store tablets at controlled room temperature between 15–30°C and protect from moisture.

Keep tablets in the original blister packaging and advise patients not to store medicines in bathrooms or cars during hot or humid weather.

Cold‑Chain Logistics For Pharmacies

No cold chain is required for bempedoic acid, but pharmacies should keep stock in air‑conditioned dispensaries in hot climates and monitor storage temperatures.

Maintain manufacturer batch records, practise first‑in first‑out stock rotation, and use overnight couriers for rural deliveries where prolonged heat exposure is a risk.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

What should pharmacists tell patients when handing over bempedoic acid?

Explain the mechanism in simple terms as an ACL inhibitor that helps the liver reduce cholesterol production and improves LDL‑C clearance.

Set expectations for LDL‑C change at 4–12 weeks, review common side effects such as gout risk, muscle spasms and liver enzyme changes, and advise on missed dose instructions.

Clarify PBS status and cost options, provide a printed fact sheet for rural patients, and refer to a GP or specialist for baseline urate and LFT monitoring as needed.

National Health Authority Recommendations

Follow TGA product information and local lipid management guidelines that recommend bempedoic acid as an adjunct to diet and maximally tolerated statin or as an alternative for statin‑intolerant adults.

Monitor uric acid and liver enzymes and report adverse events to the TGA as part of routine pharmacovigilance.

Coordinate care between the GP, cardiologist and community pharmacist for best outcomes and shared responsibility for monitoring.

Delivery Across Australia

Concluding Practical Notes

Which patients are most likely to benefit from bempedoic acid in Australia?

Adults who cannot reach LDL‑C targets on maximally tolerated statin therapy or who are intolerant of statins are the main candidates for bempedoic acid therapy.

Discuss the potential for uric acid rises and gout flares, and arrange baseline urate and liver function tests before or soon after starting therapy.

Consider stepping up to the fixed‑dose combination with ezetimibe when single‑agent LDL‑C lowering is insufficient and PCSK9 inhibitors are not accessible or indicated.

Community pharmacists are well placed to support adherence, advise on storage and transport in hot Australian climates, and triage side effects to the treating doctor.

Remember to check the current PBS Schedule for any changes to subsidy status and to report suspected adverse reactions to the TGA.